Loading condition report…
Loading condition report…
Pain that may be caused by or related to cellular, tissue, and systemic changes that occur during NEOPLASM growth, tissue invasion, and METASTASIS.
Evidence at a glance
Open any number to go directly to the underlying records.
The report maps directly scoped documents, study registrations, formulations and exact source-reported evidence. Efficacy, treatment and safety conclusions remain unvalidated. Every item links back to preserved source material. Study registrations and dose records describe what researchers reported or planned; they are not treatment advice or proof that an intervention works.
Condition scope
Subtype counts can overlap because one article may discuss more than one condition.
Research map
These are document-level associations. The first group has study-registration or regulatory context; neither group proves efficacy or clinical use.
How treatment was studied
Routes and dose values below describe registered or published research. They are not prescribing instructions.
What researchers planned or recorded in trial registrations.
No exact dose descriptions were present in this frozen report snapshot.
How the intervention was described as being given in registered studies.
Open a route to see its registrations. A study may appear under more than one route.
Source-backed observations from readable publications.
Systematic review: researchers use a documented method to find, select and assess all relevant studies for a specific question.
Meta-analysis: when the studies are sufficiently comparable, their numerical results are combined statistically.
These methods can provide a broader view than one study, but their reliability still depends on the quality and similarity of the included evidence. They do not automatically prove that a treatment works.
No publication-level dosing evidence is available in this frozen snapshot.
How the research was designed
These labels describe the registered study design—not whether the treatment worked. A study can use several methods, so categories may overlap. Protocol categories are deterministic title/type matches and use a multi-label taxonomy. Filters preserve every matching tag while each registration is shown once. Registration is not a result.
Showing 7 of 7 unique registrations. 7 pattern memberships are preserved as badges; counts may overlap.
Research frequency
Counts use the directly scoped, rights-cleared article snapshot. The current year is partial.
Registries
A registration describes the protocol. When posted, source-reported outcomes and safety are preserved on the local Study page.
Browse the complete filtered study catalog →
87 enrolled
Open study record177 enrolled
Open study record43 enrolled
Open study record11 enrolled
Open study record5 enrolled
Open study record309 enrolled
Open study record1,000 enrolled
Open study recordEnrollment not reported
Open study record660 enrolled
Open study record16 enrolled
Open study recordSupporting evidence and regulatory context
Available items are locally preserved, frozen candidates. Funding and related research remain unavailable until a complete relevance-policy-v2 section is frozen; unavailable safety linkage is never presented as zero. Source metadata and safety reports are not efficacy or causality claims.
Frozen 14/09/2026 · 3,323 records · source sync still in progress
Bone destruction from primary or metastatic cancer is associated with severe pain that is difficult to treat. Opioids are often used for cancer pain but are associated with many serious side effects, and non-opioid alternatives are needed. We will determine the effectiveness and mechanisms underlying antinociceptive properties of Resolvin D1 in a mouse model of bone cancer pain.
PROJECT NARRATIVE Controversy exists over the risk to benefit ratio of medical marijuana for adults with chronic non-cancer pain (CNCP) on chronic opioid therapy (COT). The primary goal of this proposal is to assess whether medical marijuana, when added to a behavioral prescription opioid taper support program, improves pain and reduces opioid dose in adults on COT for CNCP more so than the behavioral intervention alone. This information is critical to better inform patients and clinicians about the extent to which medical marijuana use may be beneficial or harmful to this patient population.
Relevance to public health: Pain occurs as the spread of cancer cells destroys tissue, and bone pain is among the most severe. Novel strategies are needed to treat cancer pain because of limitations to the use of opioids. Cannabinoids are potent analgesics, and manipulation of the metabolism of endogenous cannabinoids may provide an effective strategy for reducing mechanical hypersensitivity in patients where destruction of bone is involved.
Pain occurs as the spread of cancer cells destroys tissue, and bone pain is among the most severe. Novel strategies are needed to treat cancer pain because of limitations to the use of opioids. Cannabinoids are potent analgesics, and manipulation of the metabolism of endogenous cannabinoids may provide an effective strategy for reducing mechanical hypersensitivity in patients where destruction of bone is involved.
NARRATIVE The proposed study fills a major gap in knowledge about how state medical and adult-use (i.e., recreational) cannabis laws have impacted opioid receipt and pain outcomes in cancer. We will triangulate findings from a quantitative policy evaluation with information from surveys and interviews that explore cancer centers’ implementation of state cannabis laws, physicians’ practices for recommending, and patients’ practices for using cannabis for cancer pain. To inform a rapidly evolving policy landscape—in which states are continuously considering, enacting, or expanding cannabis laws— it is essential to understand how these laws affect pain management practices and outcomes for patients with cancer as one of the largest groups of consumers of therapeutic cannabis.
Relevance to public health: Pain occurs as the spread of cancer cells destroys tissue, and bone pain is among the most severe. Novel strategies are needed to treat cancer pain because of limitations to the use of opioids. Cannabinoids are potent analgesics, and manipulation of the metabolism of endogenous cannabinoids may provide an effective strategy for reducing mechanical hypersensitivity in patients where destruction of bone is involved.
Project Narrative This controlled clinical trial will investigate whether cannibidiol (CBD) is safe and effective in helping patients with chronic non-cancer pain (CNCP) disorders (who are maintained on moderate to high-doses of opioid pain medication) reduce or eliminate their chronic opioid therapy (COT) and whether CBD will be effective in reducing pain in this patient population. This investigation is significant from a public health perspective because given the limited efficacy to high risk profile of COT in CNCP, there is an urgent need to develop novel, safe, and non-addictive, non-opioid pharmacotherapies that can both reduce the dose of maintenance prescription opioids and pain in patients with CNCP syndromes.
NARRATIVE The proposed study fills a major gap in knowledge about how state medical and adult-use (i.e., recreational) cannabis laws have impacted opioid receipt and pain outcomes in cancer. We will triangulate findings from a quantitative policy evaluation with information from surveys and interviews that explore cancer centers’ implementation of state cannabis laws, physicians’ practices for recommending, and patients’ practices for using cannabis for cancer pain. To inform a rapidly evolving policy landscape—in which states are continuously considering, enacting, or expanding cannabis laws— it is essential to understand how these laws affect pain management practices and outcomes for patients with cancer as one of the largest groups of consumers of therapeutic cannabis.
PROJECT NARRATIVE Controversy exists over the risk to benefit ratio of medical marijuana for adults with chronic non-cancer pain (CNCP) on chronic opioid therapy (COT). The primary goal of this proposal is to assess whether medical marijuana, when added to a behavioral prescription opioid taper support program, improves pain and reduces opioid dose in adults on COT for CNCP more so than the behavioral intervention alone. This information is critical to better inform patients and clinicians about the extent to which medical marijuana use may be beneficial or harmful to this patient population.
Oral cancer pain, whose prevalence and intensity of pain is greater than that of other cancers, is a debilitating condition and a significant clinical challenge, in part because even the most efficacious of the currently available remedies are limited by their side effects profile. We have developed a novel class of drugs free of central nervous system side effects for treating cancer pain and propose to optimize these drugs leading to an investigational new drug (IND) approval.
PROJECT NARRATIVE Controversy exists over the risk to benefit ratio of medical marijuana for adults with chronic non-cancer pain (CNCP) on chronic opioid therapy (COT). The primary goal of this proposal is to assess whether medical marijuana, when added to a behavioral prescription opioid taper support program, improves pain and reduces opioid dose in adults on COT for CNCP more so than the behavioral intervention alone. This information is critical to better inform patients and clinicians about the extent to which medical marijuana use may be beneficial or harmful to this patient population.
Showing 12 of 22 frozen records. Browse the complete set →
Unavailable. Governed relevance linkage is not ready for this frozen snapshot; no absence of records is inferred.
No matching records in this frozen snapshot.
FAERS package linkage is unavailable; zero reports must not be inferred until exact governed medicine links are ready.
Regulatory records
Registry Results
Registry-submitted primary-outcome values are shown with exact local provenance. The service does not infer efficacy, effect direction or a treatment recommendation from these unreviewed values.
The registry has not posted a Results section for these records. A protocol does not show whether the intervention worked.No registry Results section is pinned in this frozen report snapshot.
A registration describes what was planned. It does not show whether the intervention worked.
Safety
The linked evidence is source-reported and remains candidate-only. Contraindications and patient-specific guidance are not yet validated.
Latest additions
The articles, studies and medicine records shown here are fixed to one dated snapshot. Their source identifiers and links were checked, but the platform has not turned registry entries into clinical conclusions.
This condition is normalized as D000072716 using Medical Subject Headings 2026.
9,030 source identifiers verified · snapshot record c77a894883e9...Dates are derived from this report's immutable package pins. A failed refresh does not replace the last good report.
Limits
Showing 12 of 3,279 frozen records. Browse the complete set →